Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02896569 · ClinicalTrials.gov registry record · NA
Tolerability of Using a Post-Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation
A NA study, sponsored by Venus Concept.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT02896569 is a NA study that has completed, run by Venus Concept. The registered enrollment target is 49 participants.
The verdict
NCT02896569, a NA study, has completed, sponsored by Venus Concept.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor (SCR Complex) and cytokines and a botanical lipid-based occlusive (Bio Cel) immediately following fractional radiofrequency treatment using the Venus Viva versus standard of care.
Interventions
- OTHER Topical combination therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-02-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02896569
The ClinicalTrials.gov registry entry for NCT02896569 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Venus Concept, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topical combination therapy is the first listed.
NCT02896569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02896569 about?
NCT02896569 is a clinical study titled "Tolerability of Using a Post-Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation". The purpose of this study is to compare the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor (SCR Complex) and cytokines and a botanical lipid-based occlusive (Bio Cel) immediately following fractional radiofrequency treatment u...
What is the current status of trial NCT02896569?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2016-08. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02896569?
The interventions under investigation include: Topical combination therapy (OTHER).
Who is sponsoring clinical trial NCT02896569?
This trial is sponsored by Venus Concept, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.